NXC-201 CAR-T
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Light Chain (AL) Amyloidosis
Conditions
Light Chain (AL) Amyloidosis
Trial Timeline
Jun 5, 2024 → Jan 1, 2039
NCT ID
NCT06097832About NXC-201 CAR-T
NXC-201 CAR-T is a phase 1/2 stage product being developed by Immix Biopharma for Light Chain (AL) Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06097832. Target conditions include Light Chain (AL) Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06097832 | Phase 1/2 | Recruiting |
Competing Products
5 competing products in Light Chain (AL) Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Afamelanotide (CUV1647) | Clinuvel Pharmaceuticals | Pre-clinical | 15 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Birtamimab + Standard of Care Chemotherapy | Prothena | Phase 3 | 69 |